Results - Announcements
Fredun Pharmaceuticals Ltd share price declined by 1.07% to Rs 1493.45. The Company's net profit saw a strong growth of 41.43% to Rs 18.57 crore, while revenue from operations gained 16.72% to Rs 265.85 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, gaining 5.09%. It has marginally improved by 2.18% over last one week and ticked higher by 2.72% in last one month while the market capitalization of Fredun Pharmaceuticals Ltd has improved by 9.33% and 24.30% in the same period respectively.
Profit before tax (PBT) of Fredun Pharmaceuticals Ltd stood at Rs 29.65 crore in Q3 FY26, jumping 133.28% year-on-year, and expanding by 44.28% quarter-on-quarter. EBITDA came in at Rs 42 crore, surging by 89.70% YoY and rallying 29.38% sequentially.
Total expenses advancing by 15.13% to Rs 229.21 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 241.21 crore, soaring by 34.21% YoY, while employee benefits expense was at Rs 9.11 crore, witnessing a strong rise of 27.95% YoY.
For the TTM ended FY26, revenue from operations surged 40.21% to Rs 633.33 crore, while net profit jumped 65.25% to Rs 32.62 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 5712% to Rs 94.54 crore, and PBT witnessed a strong rise of 70.97% to Rs 47.0 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 115.25 crore in FY26, as against Rs 29.06 crore in FY25.
Fredun Pharmaceuticals Ltd soared by 189.38% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 4.80% during the same period.